

Zydus Cadila's Net Profit up by 53% in Q4

Ahmedabad, May 25, 2018

Announcing the results for the fourth quarter ended 31st March 2018, Cadila Healthcare Limited informed that it has registered total income from operations of Rs. 3250 crores, up by 29% from Rs. 2513 crores registered in the corresponding period last year on a consolidated basis. On a like-to-like basis, adjusting for GST impact, the growth in total income from operations was 31%. Net Profit for the same period stood at Rs. 591 crores, up by 53%.

For the year ended 31st March 2018, the company registered a Net Profit of Rs. 1776 crores on a consolidated basis, up by 19%. Consolidated total income from operations of the company during the year stood at Rs. 11936 crores, up by 25%. On a like-to-like basis, adjusting for GST impact, the growth in total income from operations was 27%.

Strengthening its regulatory pipeline, the company filed 26 ANDAs during the year with the US FDA, taking the cumulative filings to 330. The company received 77 ANDA approvals taking the total to 186 product approvals.

During the fourth quarter, the company entered into a definitive agreement with Medicare International Inc., a subsidiary of Medicare Inc. (Medicare) to commercialize its 505(b)(2) New Drug Application (NDA) product, pitavastatin magnesium (ZYPITAMAGTM) in the United States. The launch of ZYPITAMAG, which is used to manage cholesterol levels, marks the first branded product launch for Zydus in the U.S.
